Pooled Safety Data from the risdiplam▼ clinical trial development program
FIREFISH (NCT02913482) is assessing the safety, tolerability, PK/PD and efficacy of risdiplam▼ in infants with Type 1 SMA aged 1–7 months. SUNFISH (NCT02908685) is assessing the safety, tolerability, PK/PD and efficacy of risdiplam in patients with Type 2 or 3 SMA aged 2–25 years. JEWELFISH (NCT03032172) is assessing the safety, tolerability and PK/PD of risdiplam in in non-naïve patients with SMA, aged 6 months to 60 years. This presentation reports updated pooled safety analyses from FIREFISH Parts 1 and 2, SUNFISH Parts 1 and 2 and JEWELFISH. This analysis will add to the understanding of the longer-term safety profile of risdiplam in individuals with SMA.